Emalex Biosciences is a biotech startup that develops new treatments for central nervous system disorders.
Emalex Biosciences has raised $270.0M in total funding. The most recent round was Series D. The last funding was announced in November 2022.
Emalex Biosciences's investors include Valor Equity Partners, Bain Capital Life Sciences, Fidelity, Horizon Technology Finance, Paragon Biosciences.
Emalex Biosciences is headquartered in Chicago, United States.
Emalex Biosciences is a biotech startup that develops new treatments for central nervous system disorders.
Emalex Biosciences is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Emalex Biosciences — Funding & Investors." VCBacked, November 3, 2022, https://www.vcbacked.co/company/emalex-biosciences. Accessed August 14, 2026.
VCBacked. (2022). Emalex Biosciences — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/emalex-biosciences
{{cite web |title=Emalex Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/emalex-biosciences |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated